Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients

This study has suspended participant recruitment.
Sponsor:
Collaborators:
Central and Eastern European Oncology Group
Stowarzyszenie Ludzi Wyleczonych z Raka Płuca
Pharmacia
Information provided by:
Medical University of Gdansk
ClinicalTrials.gov Identifier:
NCT00211952
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The aim of the study is to assess the influence of celecoxib on relapse-free survival in completely resected patients with poor prognosis indicated by metastatic involvement of intrapulmonary/hilar (pN1) or ipsilateral mediastinal (pN2) lymph nodes. Celecoxib, a selective oral COX-2 inhibitor, was found to exert significant anti-proliferative activity against a variety of tumor cell lines in vitro, including NSCLC. COX-2 is frequently up-regulated in NSCLC cell lines and archival tumor samples. Its high expression was also correlated with poor prognosis of the patients. A clinical trial addressing the role of celecoxib as adjuvant treatment in radically operated patients with high risk of relapse is warranted.


Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: celecoxib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo Controlled Phase III Trial Evaluating the Role of Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) Non-Small Cell Lung Cancer (NSCLC) Patients

Resource links provided by NLM:


Further study details as provided by Medical University of Gdansk:

Primary Outcome Measures:
  • time to progression

Secondary Outcome Measures:
  • overall survival
  • toxicity

Estimated Enrollment: 542
Study Start Date: March 2004
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Eligibility criteria:

  • Completely resected (R0), histologically confirmed NSCLC with pathological T1-T3 category and pathological proof of N1 or N2 disease
  • Adequate pre-surgical disease assessment (chest CT and upper abdominal CT – mandatory; mediastinoscopy or PET mandatory if clinical N2 is suspected on chest CT; other examinations according to signs and symptoms to exclude metastatic disease)
  • Adequate lymph node sampling
  • Randomization between 14 and 42 days after surgery
  • Adequate post-surgical recovery
  • Age > 18 years
  • WHO Performance Status 0 or 1
  • Adequate liver and renal function (ALT < 1.5 ULN, bilirubin within normal limits, creatinine < 1.5 ULN) and adequate haematology (haemoglobin >11g/dL, WBC>2.000/L, PLT>100.000/L)
  • Written informed consent
  • No previous treatment with chemotherapy
  • No histological diagnosis of SCLC or mixed NSCLC/SCLC type
  • No apparent involvement of mediastinal lymph nodes at preoperative staging (cN2)
  • No evidence of metastatic disease (M1)
  • Stable medical conditions (e.g. no myocardial infarction within 12 months, unstable angina, active psychiatric disorder)
  • No active infection
  • No history of malignancy other than basal-cell skin cancer or in situ cervical cancer
  • No history of severe renal or liver insufficiency
  • No history of a recent gastrointestinal bleeding or active ulcer disease or extensive gastro-intestinal surgery that may affect the drug absorption
  • No participation in any investigational study within 30 days prior to enrollment
  • No pregnancy or lactation or inadequate contraception
  • No known hypersensitivity to celecoxib, other COX-2 inhibitors or aspirin (aspirin triad)
  • No chronic use of NSAID’s (selective inhibitors of COX-2 and non- selective COX inhibitors), acetylsalicylic acid (aspirin) nor oral steroids >14 days during one month prior to surgery nor anticipated chronic use of the above drugs during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00211952

Locations
Poland
Medical University of Gdansk
Gdansk, Poland, 80-211
Sponsors and Collaborators
Medical University of Gdansk
Central and Eastern European Oncology Group
Stowarzyszenie Ludzi Wyleczonych z Raka Płuca
Pharmacia
Investigators
Principal Investigator: Jacek Jassem, Professor Medical University of Gdansk
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00211952     History of Changes
Other Study ID Numbers: 0102 PLCSG
Study First Received: September 13, 2005
Last Updated: September 13, 2005
Health Authority: Poland: Ministry of Health

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Celecoxib
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014